Indivumed, Personalis partner on personalized oncology therapies

By The Science Advisory Board staff writers

April 21, 2020 -- Indivumed and Personalis are joining forces in a collaboration aimed at enabling personalized oncology treatments.

Under the partnership, Indivumed's IndivuType multiomics cancer database will be paired with genome and transcriptome-level data from thousands of samples using Personalis' cancer genomics technology, according to the firms. Pairing the two platforms will provide innovative solutions for tumor genomics characterization and insights into oncology therapeutics.

Indivumed CEO and Founder Dr. Hartmut Juhl said that adding Personalis' technology to the IndivuType multiomics profile will enable relevant discoveries in the firm's pharma and biotech collaborations and further its mission of advancing precision oncology.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.